Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. (Q38447982)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Geoffrey Liu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Suzanne Kamel-Reid

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Gilda da Cunha Santos

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

C Lim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

L W Le

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

F A Shepherd

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

R Feld

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

R L Burkes

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

D Hwang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

J Tanguay

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

N B Leighl

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

28 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

1415-1421

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV208

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV208

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV208

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV208

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV208

Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/In

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV208

Tumour molecular profiling for deciding therapy-the French initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV208

Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV208

Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV208

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV208

Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV208

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV208

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922063%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference